Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as a leading cause of chronic liver disease. In recent years, artificial intelligence (AI) has attracted significant attention in healthcare, particularly in diagnostics, patient management, and drug development, demonstrating immense potential for application and implementation. In the field of MASLD, substantial research has explored the application of AI in various areas, including patient counseling, improved patient stratification, enhanced diagnostic accuracy, drug development, and prognosis prediction. However, the integration of AI in hepatology is not without challenges. Key issues include data management and privacy, algorithmic bias, and the risk of AI-generated inaccuracies, commonly referred to as “hallucinations”. This review aims to provide a comprehensive overview of the applications of AI in hepatology, with a focus on MASLD, highlighting both its transformative potential and its inherent limitations.
代谢功能障碍相关脂肪性肝病正逐渐成为慢性肝病的主要病因。近年来，人工智能在医疗健康领域，特别是在疾病诊断、患者管理和药物研发方面受到广泛关注，展现出巨大的应用潜力。在代谢功能障碍相关脂肪性肝病领域，已有大量研究探索人工智能在患者咨询、优化患者分层、提高诊断准确性、药物研发及预后预测等多方面的应用。然而，人工智能在肝病学领域的整合仍面临诸多挑战，主要包括数据管理与隐私保护、算法偏见以及人工智能生成错误信息（通常称为“幻觉”）的风险。本文旨在全面综述人工智能在肝病学，特别是代谢功能障碍相关脂肪性肝病领域的应用，重点阐述其变革潜力与固有局限性。
Revolutionizing MASLD: How Artificial Intelligence Is Shaping the Future of Liver Care
肿瘤(癌症)患者之家